Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;39(12):2230-2241.
doi: 10.1002/mds.30020. Epub 2024 Sep 18.

Unilateral Magnetic Resonance-Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson's Disease: A Prospective Study

Affiliations

Unilateral Magnetic Resonance-Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson's Disease: A Prospective Study

Laura Armengou-Garcia et al. Mov Disord. 2024 Dec.

Abstract

Background: Unilateral subthalamic nucleus (STN) ablation using magnetic resonance-guided focused ultrasound (MRgFUS) is being explored as a new treatment for asymmetric Parkinson's disease (PD).

Objectives: The aims were to study the efficacy and safety of this treatment in asymmetric PD patients and to characterize the lesions.

Methods: This prospective, single-center, open-label study evaluated asymmetric PD patients at 6 (n = 20) and 12 months (n = 12) after MRgFUS lesion of the STN. The primary outcome was the change in the Movement Disorders Society-Unified Parkinson's Disease Rating Scale, Part III (MDS-UPDRS III), score in off medication on the treated side and the adverse events (AEs) at 6-month follow-up. We also evaluated cognitive-neuropsychological changes, self-assessment of clinical improvement, and the correlation of the lesion volume with the motor outcomes.

Results: On the treated side, the MDS-UPDRS III score (mean difference = 13.8) and the scores in rigidity, bradykinesia, and tremor improved (P < 0.001) throughout the follow-up compared to baseline (at 6 months: rigidity mean difference = 2.8, improvement: 83.5%; bradykinesia mean difference = 6.0, improvement: 69.4%; tremor mean difference = 4.7, improvement: 91.5%). One patient had severe weakness in the treated hemibody, 1 had moderate dyskinesia, and 1 was in moderate confusional state that became mild (weakness) or completely resolved (dyskinesia and confusional state) at 6 months. The rest of the AEs were mild. We observed no clinically relevant changes in cognitive-neuropsychological tests. The percentage of ablation of the STN correlated with the improvement in the total MDS-UPDRS III and contralateral tremor scores (P < 0.05).

Conclusion: Unilateral MRgFUS lesion of the STN resulted in a significant motor improvement. We observed no persistent severe AEs, although mild, mostly transient AEs were frequent. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; magnetic resonance–guided focused ultrasound; subthalamic nucleus (STN).

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
(A) T1‐weighted images showing the STN (subthalamic nucleus) lesion. Correlation between the percentage of ablated STN and the reduction (B) in the MDS‐UPDRS III (Movement Disorders Society‐Unified Parkinson's Disease Rating Scale, Part III) total score, (C) in the tremor score on the treated side, (D) in the akinesia score on the treated side, and (E) in the total score of MDS‐UPDRS III on the treated side.
FIG. 2
FIG. 2
(A) Change in the MDS‐UPDRS III (Movement Disorders Society‐Unified Parkinson's Disease Rating Scale, Part III) scores on the treated side during follow‐up. (B) Mean percentage of improvement in the MDS‐UPDRS III score on the treated side of each patient 6 months after treatment. (C) Patient Global Impression of Change (PGI‐C) during follow‐up. [Color figure can be viewed at wileyonlinelibrary.com]

Similar articles

Cited by

References

    1. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007;64(1):20–24. 10.1001/archneur.64.1.20 - DOI - PubMed
    1. Obeso JA, Rodríguez‐Oroz MC, Benitez‐Temino B, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord 2008;23(Suppl 3):S548–S559. 10.1002/mds.22062 - DOI - PubMed
    1. Wichmann T, Bergman H, DeLong MR, The primate subthalamic nucleus. III . Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 1994;72(2):521–530. 10.1152/jn.1994.72.2.521 - DOI - PubMed
    1. Guridi J, Herrero MT, Luquin MR, et al. Subthalamotomy in parkinsonian monkeys Behavioural and biochemical analysis. Brain 1996;119:1717–1727. - PubMed
    1. Gill SS, Heywood P. Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease. Lancet 1997;350(9086):1224. 10.1016/s0140-6736(05)63455-1 - DOI - PubMed